This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Inclusion Criteria All Cohorts * Age ≥ 18 years (≥20 years for Japan only) at screening * Signed and dated written informed consent in accordance with GCP (Good Clinical Practice ) and local legislation prior to admission to the trial * WHO/ECOG (World Health Organization / Eastern Cooperative Oncology Group) performance status 0-1 assessed at screening * Patient must be able to swallow oral capsules or tablets Cohort A (Solid Tumours) \& Cohort E (NSCLC): \- Male or female patients ready and able to use highly effective methods of birth control during the study and for 3 weeks following the last dose of abemaciclib per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. Women of childbearing potential must have a negative serum pregnancy test at screening. Cohort A (Solid Tumours) * Patients with histologically or cytologically confirmed diagnosis of advanced and/or metastatic, measurable or evaluable, non-resectable solid tumours * Patients must have received and failed, or have been intolerant to, all treatment known to confer clinical benefit or have no therapeutic options available as deemed appropriate by their treating physician * Life expectancy ≥ 3 months in the opinion of the investigator assessed at screening; Cohorts B, C, D (dose finding, Breast Cancer) \& Cohort D1 and Cohort D2 (Breast Cancer): * Women w…